Evidence reviews - September 2023
The following documents contain the evidence that was used to develop the 2023 recommendations:
- Clinical and cost-effectiveness of non-selective beta-blockers and endoscopic variceal band ligation for the primary prevention of bleeding in people with oesophageal varices due to cirrhosis
- Use of antibiotics to prevent spontaneous bacterial peritonitis
- Clinical and cost effectiveness of non-selective beta-blockers for the primary prevention of decompensation in people with compensated cirrhosis
Other supporting evidence
These documents preserve evidence reviews and committee discussions for areas of the guideline that were not updated in 2023.
This page was last updated: